NPAT

Woodside Releases Full-Year 2023 Results

Retrieved on: 
Monday, February 26, 2024

Woodside CEO Meg O’Neill said she was tremendously proud that at a time of inflationary pressures, Woodside continued to return strong dividends to shareholders while delivering on our strategy to thrive through the energy transition.

Key Points: 
  • Woodside CEO Meg O’Neill said she was tremendously proud that at a time of inflationary pressures, Woodside continued to return strong dividends to shareholders while delivering on our strategy to thrive through the energy transition.
  • “Woodside is supplying energy the world needs from a high-quality portfolio which is geographically advantaged to meet growing demand for LNG.
  • “The Scarborough Energy Project received four key environmental approvals in December 2023 and was 55% complete at the end of the year.
  • We also commenced concept select for Angel carbon capture and storage, which has the potential to address Woodside Scope 1 emissions and customer emissions.

Comvita Announces Strong Earnings Improvement

Retrieved on: 
Thursday, August 26, 2021

TAURANGA, New Zealand, Aug. 26, 2021 /PRNewswire/ -- Comvita (NZX:CVT) today released its full year audited results for the year ending 30thJune 2021, reporting a full year EBITDA at the top end of its market guidance at $25.5M. This represents an increase of +511% versus the prior corresponding period (PCP) driven by strong performance in its focus growth markets, focus channels and categories, underpinned by $12.1M of benefits from its transformation programme over the last 18 months.

Key Points: 
  • Comvita Chair Brett Hewlett commented, "As I shared at the Annual Shareholder Meeting in October 2020, FY21 was a crucial year for Comvita as we looked to prove the significant potential that exists to all stakeholders.
  • We are pleased to report strong earnings growth at the top end of guidance, good management of cash and working capital and to be able to reward our shareholders with the resumption of dividends.
  • Despite increasing marketing investment by 139% versus PCP, net contribution increased by 25% as top line growth translated to strong earnings improvement.
  • Comvita continued its strong performance in both its focus Mnuka honey category and in the digital channel with both recording double digit top and bottom-line growth.

Comvita Announces Strong Earnings Improvement

Retrieved on: 
Thursday, August 26, 2021

TAURANGA, New Zealand, Aug. 25, 2021 /PRNewswire/ -- Comvita (NZX:CVT) today released its full year audited results for the year ending 30thJune 2021, reporting a full year EBITDA at the top end of its market guidance at $25.5M. This represents an increase of +511% versus the prior corresponding period (PCP) driven by strong performance in its focus growth markets, focus channels and categories, underpinned by $12.1M of benefits from its transformation programme over the last 18 months.

Key Points: 
  • Comvita Chair Brett Hewlett commented "As I shared at the Annual Shareholder Meeting in October 2020, FY21 was a crucial year for Comvita as we looked to prove the significant potential that exists to all stakeholders.
  • We are pleased to report strong earnings growth at the top end of guidance, good management of cash and working capital and to be able to reward our shareholders with the resumption of dividends.
  • Despite increasing marketing investment by 139% versus PCP, net contribution increased by 25% as top line growth translated to strong earnings improvement.
  • Comvita continued its strong performance in both its focus Mnuka honey category and in the digital channel with both recording double digit top and bottom-line growth.

BetterLife Pharma Issues Update on its Promotional Activity

Retrieved on: 
Friday, July 24, 2020

Vancouver, July 24, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (OTCQB:BETRF / CSE: BETR /FRA: NPAT) provides the following information about certain promotional activities at the request of OTC Markets.

Key Points: 
  • Vancouver, July 24, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (OTCQB:BETRF / CSE: BETR /FRA: NPAT) provides the following information about certain promotional activities at the request of OTC Markets.
  • Upon immediate inquiry BetterLife determined that the aforementioned promotional emails were sent by National Inflation Association.
  • The Company believes the promotional activity may have been a factor with respect to an increased price and trading volume concerning the Company's common shares that occurred on July 22, 2020 following the promotional activity.
  • BetterLife Pharma Inc. is a science-based innovative medical wellness company aspiring to offer high-quality preventive and self-care products to its customers.

BetterLife Pharma Confirms Re-Pricing of Warrants

Retrieved on: 
Tuesday, May 12, 2020

VANCOUVER, May 12, 2020 /PRNewswire/ -BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) confirms the re-pricing of warrants issued pursuant to financings completed in 2019 as announced in the Company's press release dated May 7, 2020.

Key Points: 
  • VANCOUVER, May 12, 2020 /PRNewswire/ -BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) confirms the re-pricing of warrants issued pursuant to financings completed in 2019 as announced in the Company's press release dated May 7, 2020.
  • Warrantholders may exercise their warrants by returning a completed subscription notice/form (included with the warrant certificate), the original warrant certificate and payment by bank draft (made payable to "BetterLife Pharma Inc.") to the Company's legal counsel at: Alexander, Holburn, Beaudin + Lang LLP, #2700-700 West Georgia Street, Vancouver, BC V7Y 1B8 (C/O BetterLife Pharma Inc.).
  • BetterLife Pharma Inc. is a science-based innovative medical wellness company aspiring to offer high-quality preventive and self-care products to its customers.
  • BetterLife does not undertake any obligation to update such forward-looking statements, except as required by law.

Pivot Pharma appoints Toni Rinow as new Chief Executive Officer

Retrieved on: 
Monday, August 19, 2019

VANCOUVER, Aug. 19, 2019 /PRNewswire/ -Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) is pleased to announce today that its board of directors has appointed Toni Rinow as Chief Executive Officer and Dr. Renz as Regional Manager Europe in addition to serving as its Chief Medical Officer.

Key Points: 
  • VANCOUVER, Aug. 19, 2019 /PRNewswire/ -Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) is pleased to announce today that its board of directors has appointed Toni Rinow as Chief Executive Officer and Dr. Renz as Regional Manager Europe in addition to serving as its Chief Medical Officer.
  • Under Dr. Toni Rinow's leadership, Pivot will be put on a path of accelerated revenue growth and global expansion in key cannabis markets in Canada, United States, and the European Union.
  • Dr. Rinow believes in giving back to the community and sits on the Board of Directors of several non-for profit organizations.
  • "Pivot is transformational to the cannabis market by bringing superior, science-based, high quality and innovative products to the consumer market.

Pivot Pharmaceuticals Signs Agreement with Licorera Del Sur Subsidiary Cartagena Inc. To Create Joint Venture To Commercialize Cannabis-Infused Non-Alcoholic Beverages

Retrieved on: 
Monday, October 22, 2018

(CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") is pleased to announce that it has signed a Letter of Intent to create a Joint Venture ("the Joint Venture") with Cartagena Inc. , a subsidiary of Mexico-based Licorera Del Sur .

Key Points: 
  • (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") is pleased to announce that it has signed a Letter of Intent to create a Joint Venture ("the Joint Venture") with Cartagena Inc. , a subsidiary of Mexico-based Licorera Del Sur .
  • In addition, the Pivot and Cartagena Joint Venture will have extensive access to sales, distribution and marketing expertise.
  • Mr. Paul Bou-Nader, Managing Director of Cartagena Inc. stated "We are excited to partner with Pivot to create low calorie, rapid onset cannabis-infused beverages.
  • Dr. Patrick Frankham, CEO of Pivot stated, "We are thrilled that Cartagena Inc. has agreed to enter into this Joint Venture.

Pivot Signs Exclusive Co-Marketing And Distribution Agreement with Swiss-based S.T.U. GmbH, Establishes Large Retail and Online Sales Channels In The European Union

Retrieved on: 
Thursday, August 2, 2018

(CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") is pleased to announce that it has entered into a Definitive Co-marketing and Distribution Agreement ("the Agreement") with S.T.U.

Key Points: 
  • (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") is pleased to announce that it has entered into a Definitive Co-marketing and Distribution Agreement ("the Agreement") with S.T.U.
  • will market and sell Pivot's proprietary cannabinoid-derived products online and in retail outlets in the U.K., Switzerland, Germany, Austria and Italy (where regulations permit).
  • Pivot Naturals branded products to be distributed and sold in the EU by S.T.U.
  • We look forward to introducing the "Pivot Naturals" brand of topical creams and lotions, oral solutions and capsules to our customers via our growing retail and online sales channels."